Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Peripheral T-cell Lymphoma Clinical Trial

Official title:

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients Previously Undiagnosed Peripheral T-cell Lymphoma Who Achieved an Objective Response After Initial Treatment With CHOP-based Chemotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01420679
• Other study ID #: PDX-017
• Secondary ID: 2010-022230-81
• Status: Terminated
• Phase: Phase 3
• Start date: August 2011
• Est. completion date: December 2017

Study information

• Verified date: November 2021
• Source: Spectrum Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in patients with partial response following CHOP-based chemotherapy. Patients will either receive pralatrexate or be under observation. All patients will receive vitamins B12 and folic acid and attend regular clinic visits to evaluate their disease and health.

Description:

This was an international, multi-center, randomized, Phase 3, open-label study of sequential pralatrexate versus observation in patients with previously undiagnosed PTCL who have achieved an objective response following initial treatment with CHOP-based chemotherapy.

Upon documentation of completion of an objective response following at least 6 cycles of a designated CHOP-based chemotherapy confirmation of histopathology by independent review, and confirmation that all eligibility criteria were met, patients were randomized in a 2:1 ratio to either pralatrexate or observation, according to a permuted block design with stratification factor of Tumor Response per Investigator at completion of CHOP-based therapy (Complete Response [CR] vs Partial Response [PR]).

All patients who receive at least 1 dose of pralatrexate were followed for safety through 35 (± 5) days after their last dose of pralatrexate or until all treatment-related AEs have resolved or returned to baseline/Grade 1, whichever is longer, or until it was determined that the outcome does not change with further follow-up.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification:

• T/natural killer (NK)-cell leukemia/lymphoma

• Adult T-cell lymphoma (TCL)/leukemia (human T-cell leukemia virus 1+)

• Angioimmunoblastic TCL

• Anaplastic large cell lymphoma (ALCL), primary systemic type, excluding anaplastic lymphoma kinase positive (ALK+) with International Prognostic Index (IPI) score less than 2 at initial diagnosis and complete response (CR) after CHOP-based therapy

• PTCL-unspecified

• Enteropathy-type intestinal lymphoma

• Hepatosplenic TCL

• Subcutaneous panniculitis TCL

• Transformed mycosis fungoides (tMF)

• Extranodal T/NK-cell lymphoma nasal or nasal type

• Primary cutaneous gamma-delta TCL

• Primary cutaneous CD8+ aggressive epidermic cytotoxic TCL

• Documented completion of at least 6 cycles of CHOP-based therapy:

• CHOP 21

• CHOP 14

• CHOP + etoposide

• Other CHOP variants: substitution allowed for 1 component with a drug of the same mechanism of action. Additional components, except alemtuzumab, are allowed. Rituximab may be added if not given within 3 cycles of randomization.

• Patient has achieved CR or partial response (PR) per per investigator's assessment following completion of CHOP-based therapy and has had radiological assessment within 21 days prior to randomization.

• Eastern Cooperative Oncology Group performance status less than or equal to 2.

• Adequate blood, liver, and kidney function as defined by laboratory tests.

• Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.

• Men who are sexually active, including those with a pregnant partner, must agree to practice a medically acceptable barrier method contraceptive regimen (eg, condoms) while receiving pralatrexate and for 90 days after the last administration of pralatrexate.

• Has given written informed consent.

Exclusion Criteria:

• Patient has:

• Precursor T/NK neoplasms

• ALCL (ALK+) with IPI score less than 2 at initial diagnosis and CR after CHOP-based therapy

• T cell prolymphocytic leukemia

• T cell large granular lymphocytic leukemia

• Mycosis fungoides, except tMF

• Sézary syndrome

• Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

• If there is a history of prior malignancies other than those below, must be disease free for at least 5 years. Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.

• non-melanoma skin cancer

• carcinoma in situ of the cervix

• localized prostate cancer

• localized thyroid cancer

• Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except:

• Patients with nasal NK lymphoma who received local RT less than 4 weeks prior to randomization.

• Patients with tMF who received 1 systemic single-agent CT (except methotrexate) prior to transformation.

• Prior exposure to pralatrexate.

• Receipt of systemic corticosteroids within 3 weeks of study treatment, unless patient has been taking a continuous dose of 10 mg/day or less of oral prednisone or equivalent for at least 4 weeks or as part of a CHOP prednisone taper.

• Planned use of any treatment for PTCL during the course of the study.

• Patient has:

• Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.

• Hepatitis B (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria. Other antiviral therapies are permitted if at a stable dose for at least 4 weeks.

• Hepatitis C (HCV) virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.

• Symptomatic central nervous system metastases or lesions requiring treatment.

• Uncontrolled hypertension or congestive heart failure Class III/IV per the New York Heart Association's Heart Failure Guidelines

• Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness impairing the ability of the patient to receive protocol treatment.

• Major surgery within 2 weeks prior to study entry, except for line placement or biopsy procedure.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Peripheral T-cell Lymphoma

Intervention

Drug:
• Pralatrexate Injection
Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 30 mg/m2 Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Flinders Medical Center	Bedford Park	South Australia
Australia	Monash Medical Centre	Clayton	Victoria
Australia	Saint Vincent's Hospital Melbourne	Fitzroy	Victoria
Australia	Frankston Hospital	Frankston	Victoria
Australia	Royal Hobart Hospital	Hobart	Tasmania
Australia	Cabrini Health	Malvern	Victoria
Australia	Royal Perth Hospital	Perth	Western Australia
Belgium	AZ Sint-Jan	Brugge
Belgium	Universitair Ziekenhuis Gent	Gent
Canada	Hôpital du Sacré-Coeur de Montréal	Montreal	Quebec
Canada	Sunnybrook Health Science Centre	Toronto	Ontario
France	Hôpital Morvan	Brest
France	CHU Haut-Leveque	Pessac
Ireland	St James Hospital	Dublin 8
Israel	Hadassah Ein-Kerem Medical Centre	Jerusalem
Israel	Shaare Zedek Medical Center	Jerusalem
Israel	Rabin Medical Center	Petach Tikva
Israel	Chaim Sheba Medical Center	Tel Hashomer
Italy	Az. Ospedaliera Universitaria S. Orsola Malpighi	Bologna
Italy	Spedali Civili di Brescia	Brescia
Italy	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori	Meldola	Forli
Italy	Ospedale S. Maria delle Croci	Ravenna
Italy	Università Cattolica del Sacro Cuore	Roma
Italy	Az. Ospedaliera Università Senese	Siena
New Zealand	Auckland City Hospital / Auckland University	Auckland
New Zealand	Christchurch Hospital	Christchurch
New Zealand	North Shore Hospital	Milford
New Zealand	Middlemore Hospital	Otahuhu	Auckland
Poland	Dept of Hematology and Transplantology	Gdansk
Poland	Malopolskie Centrum Medyczne	Kraków
Poland	Klinika Nowotworów Ukladu Chlonnego Centrum Onkologii Instytut Marii Sklodowskiej-Curie	Warszawa	Mazowieckie
Puerto Rico	Auxilio Mutuo Cancer Center	San Juan
Spain	Complejo Hospitalario Universitario A Coruña- Hospital A Coruña	A Coruña
Spain	Hospital Clínic i Provincial de Barcelona	Barcelona
Spain	Hospital General Vall d'Hebron	Barcelona
Spain	Hospital de Madrid Norte-Sanchinarro	Madrid
Spain	Hospital Universitario Puerta de Hierro Majadahonda	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Clinica Universidad de Navarra	Pamplona	Navarra
Spain	Complejo Hospitalario de Navarra, Servicio de Hematologia	Pamplona	Navarra
United Kingdom	Antrim Area Hospital	Antrim	Northern Ireland
United Kingdom	Belfast City Hospital	Belfast
United Kingdom	Velindre Hospital	Cardiff
United Kingdom	NHS Greater Glasgow and Clyde Western Infirmary	Glasgow	Scotland
United Kingdom	Royal Liverpool University Hospital	Liverpool
United Kingdom	Mount Vernon Cancer Centre	Middlesex
United Kingdom	Derriford Hospital	Plymouth	England
United Kingdom	Poole Hospital NHS Foundation Trust, Poole General Hospital	Poole	Dorset
United Kingdom	Royal Cornwall Hospital	Truro	Cornwall
United Kingdom	UHCW (University Hospital Coventry and Warwickshire)	Warwick
United Kingdom	Sandwell & West Birmingham Hospitals NHS Trust	West Bromwich	England
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	New York Presbyterian Hospital	New York	New York
United States	Detroit Clinical Research Center, PC	Novi	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Spectrum Pharmaceuticals, Inc

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  France,  Ireland,  Israel,  Italy,  New Zealand,  Poland,  Puerto Rico,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS)	PFS was defined as the time in days from randomization to the date of objective documentation of progressive disease (PD) or death, regardless of cause (date of PD or death - date of randomization + 1). PFS was to be assessed according to the International Workshop Criteria (IWC) without including positron emission tomography (PET). PD was defined as any new lesion or increase by greater than or equal to (>=) 50 percent (%) of previously involved sites from nadir. Participants who were alive without a disease response assessment of PD was to be censored at their last disease assessment date or the date of randomization, whichever was later. Date of progression was not to be imputed for participants with missing tumor assessments before an assessment of PD. Participants who withdraw from treatment prior to PD were to be followed for disease status whenever possible. Participants who have no response assessments after baseline were to be censored at randomization.	From randomization to the date of progression of disease or death due to any cause (up to 76 months)
Primary	Overall Survival (OS)	Overall survival was defined as the time in days from randomization to the date of death, regardless of cause (date of death - date of randomization + 1).	From randomization until death (up to 76 months)
Secondary	Objective Response Rate	Objective response rate was defined as percentage of participants with an objective response of complete response (CR) or partial response (PR), relative to disease status at the time of study entry. The percentage was to be calculated by dividing number of participants within each category of response by the number of participants with measurable disease at baseline. Objective response was assessed according to the IWC without including PET. CR was defined as complete disappearance all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR was defined as regression of measurable disease and no new sites.	Up to 2 years
Secondary	Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities	An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. AE included both serious and non- SAEs. An AE of "Hematology and Chemistry" was collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening and Grade 4 refers to life-threatening consequences.	From first dose of study drug to 35 (±5) days after last dose of study drug for the Pralatrexate Arm, and until 35 (± 5) days after the study treatment discontinuation for the Observation Arm (Up to 2 years)